Abacavir + lamivudine
Generic name
Abacavir + lamivudine
Brand name
ATC Code
J05AR02
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
When administered to children, abacavir is absorbed well and rapidly from oral formulations. Paediatric pharmacokinetic studies have shown that once-daily dosing has an equivalent AUC 24 to twice-daily dosing of the same total daily dose for both the oral solution and the tablet formulations.
The absolute bioavailability of lamivudine (approximately 58 to 66%) was lower and more variable among paediatric patients under 12 years of age. The paediatric pharmacokinetic studies with tablet formulations have however shown that once-daily dosing has an equivalent AUC 24 to twice-daily dosing of the same total daily dose.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Treatment HIV infection |
|---|
|
Renal impaiment in children > 3 months
creatinine clearance < 50 ml/min: do not use, given that the dose adjustments required are not possible with the combination tablet.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
DIRECT ACTING ANTIVIRALS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Nucleosides and nucleotides excl. reverse transcriptase inhibitors | ||
|---|---|---|
| J05AB01 | ||
| J05AB04 | ||
| J05AB11 | ||
| J05AB14 | ||
| Protease inhibitors | ||
|---|---|---|
| J05AE10 | ||
| J05AE03 | ||
| Nucleoside and nucleotide reverse transcriptase inhibitors | ||
|---|---|---|
| J05AF10 | ||
| J05AF05 | ||
| J05AF01 | ||
| Non-nucleoside reverse transcriptase inhibitors | ||
|---|---|---|
| J05AG01 | ||
| Neuraminidase inhibitors | ||
|---|---|---|
| J05AH02 | ||
| Antivirals for treatment of HIV infections, combinations | ||
|---|---|---|
| J05AR10 | ||
| Other antivirals | ||
|---|---|---|
| J05AX12 | ||
| J05AX08 | ||
| ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS | ||
|---|---|---|
| J05AR10 | ||
| Antivirals for treatment of HCV infections | ||
|---|---|---|
| J05AP57 | ||
| J05AP08 | ||
| J05AP55 | ||
Reference
- ViiV Healthcare UK Limited, SmPC Kivexa (EU/1/04/298/001-004) 17-11-14, www.cbg-meb.nl
Changes
Therapeutic Drug Monitoring
Overdose
